Alan Lewis is the president and chief executive officer of Diavacs, a biotechnology company that offers dendritic cell therapy for autoimmunity and juvenile diabetes. He also serves as the chairman of the board at Batu Biologics and Cellastra, a board member at Targazyme and BioMarin, and the acting chief executive officer of Capella Therapeutics.. Lewis has also provided his services as the president and chief executive officer of many other companies, including Medistem, Ambit Biosciences, Juvenile Diabetes Foundation, Novocell, and Signal Pharmaceuticals.. Lewis holds a bachelor’s degree in physiology and biochemistry from the University of Southampton and PhD in pharmacology from the University of Wales. He completed his postdoctoral training at Yale University.. Lewis resides in San Diego, California, United States.
